Pregledni rad

Does Prostate Specific Antigen (PSA) Screening Reduce Prostate Cancer Mortality?

Igor Tomašković

Sažetak

In spite of the fact that prostate cancer is one of the deadliest malignancies in men, the effect of prostate-specific antigen (PSA) screening on prostate cancer mortality remains debated. The European Randomized Study of Screening for Prostate Cancer (ERSPC) demonstrated a statistically significant 27% decrease in prostate cancer-specific mortality after 13 years of follow-up in screened vs. Unscreened men. In contrast, the prostate arm of the US Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) found no benefit from screening. Irrespective of mortality impact, favourable results from prostate cancer screening include an increasing number of men with localised disease and an increase in the number of well-differentiated tumours. However, the risk of overdiagnosis and subsequent overtreatment, including its effects on the quality of life, offers arguments against screening. The present knowledge requires a review of the previous recommendations on the use of PSA.

Ključne riječi

prostate-specific antigen; PSA, screening; early detection; prostate cancer

Hrčak ID:

144634

URI

https://hrcak.srce.hr/144634

Datum izdavanja:

8.9.2015.

Podaci na drugim jezicima: hrvatski

Posjeta: 2.472 *